Dermatology

This Q&A interview with Mona Shahriari, MD, highlights key atopic dermatitis tips, new developments, and themes from her session at RAD 2026.

Mona Shahriari, MD, spoke about the evolving understanding of atopic dermatitis as a systemic disease, the complexities of treatment selection, and more.

Multiple trials at RAD 2026 highlight the efficacy and safety of delgocitinib in chronic hand eczema.

RAD 2026 data indicate tralokinumab achieved significantly deeper hand eczema clearance and greater functional improvement than dupilumab in an indirect comparison.

Roflumilast cream data from RAD 2026 shed further light on the efficacy and safety across the age spectrum.

Nguyen urges clinicians to consider patient's disease presentation, comorbidities, treatment goals, and preferences when making therapeutic decisions.

At RAD 2026, Nguyen speaks on key highlights from his “Medical Crossfire” session, touching on the atopic dermatitis treatment landscape.

David Rosmarin, MD, discussed STAT6 inhibitors, ITK inhibitors, bispecifics, hand eczema, and endpoints at the RAD 2026 Conference.

At SDPA 2026, Shanna Miranti, PA-C, outlined how dermatology PAs can sharpen diagnostic speed and accuracy through structured visual practice and algorithm-based thinking.

Song emphasized that clinicians should think beyond the skin when managing patients with atopic dermatitis.

ARCADIA LTE data show nemolizumab maintains EASI-75 in over 90% of responders through 2 years and phase 2 pediatric data shed further light at RAD 2026.

At RAD2026, Lieberman notes advances in immunology and systemic therapies that are reshaping the link between dermatology and allergy/immunology.

A propensity-matched study shows dupilumab reduces gastrointestinal and endocrine IMID risk by 43-46% but raises psoriasis risk by 24%.

Lieberman, spoke at RAD 2026 about highlights from his session, ‘Connecting AD to Other Dermatologic Disorders and Related Comorbidities.'

RAD 2026 analyses reveal the impact of CHE on patients' lives, including its financial effects and influence on treatment decision-making.

Real-world data from the international TRACE study show 12 months of tralokinumab improved skin and quality-of-life outcomes.

DiRuggiero on PsO-LD, a heating pad for molluscum, and why psoriasis counseling must now include pulmonary risk.

This video feature highlights the views of dermatologists on prior authorization, step therapy, and issues related to these processes.

Dermatologists write up to 10% of US antibiotics. At SDPA 2026, Douglas DiRuggiero, PA-C, explains why that must change and what to use instead.

Phase 3 VITESSE subgroup data show response rates of 46% to 48% in children with peanut allergy and concomitant asthma, atopic dermatitis, or food allergies, says David Fleischer, MD.

In her SDPA interview, Min discusses dermatology and rheumatology collaboration, exploring treatment options for connective tissue disease.

This SDPA interview highlights the connection between dermatology and rheumatology, noting diagnoses that can be challenging for rheumatologists.

This SDPA Summer Conference interview with Lisa Swanson, MD, highlights several notable treatment options for molluscum and hemangiomas.

At SDPA, Swanson highlighted a variety of key tips for clinicians, including strategies for treating hemangiomas and warts in children.

This Q&A interview highlights ways to counsel patients regarding the safety of various sunscreens, photoprotection, and UV radiation's impact on skin cancer.